B-cell maturation protein, which binds the tumor necrosis factor family members BAFF and APRIL, is dispensable for humoral immune responses - PubMed (original) (raw)
B-cell maturation protein, which binds the tumor necrosis factor family members BAFF and APRIL, is dispensable for humoral immune responses
S Xu et al. Mol Cell Biol. 2001 Jun.
Abstract
B-cell maturation protein (BCMA) is a member of the tumor necrosis factor (TNF) receptor family and is expressed in B lymphocytes. BCMA binds two TNF family members, BAFF and APRIL, that stimulate cellular proliferation. BAFF in particular has been shown to influence B-cell survival and activation, and transgenic mice overexpressing BAFF have a lupus-like autoimmune disorder. We have inactivated BCMA in the mouse germ line. BCMA(-/-) mice have normal B-cell development, and the life span of mutant B lymphocytes is comparable to that of wild-type B cells. The humoral immune responses of BCMA(-/-) mice to T-cell-independent antigens as well as high and low doses of T-cell-dependent antigens are also intact. In addition, mutant mice have normal splenic architecture, and germinal centers are formed during an ongoing immune response. These data suggest a functional redundancy of BCMA in B-cell physiology that is probably due to the presence of TACI, another TNF receptor family member that is expressed on B cells and that can also bind BAFF and APRIL.
Figures
FIG. 1
Gene inactivation of BCMA. (A) Partial restriction endonuclease map of the wild-type allele, the targeting vector, and the inactivated allele of BCMA (B, _Bam_HI; E, _Eco_RI; H, _Hin_dIII; X, _Xho_I; pBKS, pBluescript KS). The black boxes represent exons. _Hin_dIII digestion of the genomic DNA will yield fragments of 8 and 6 kb for the wild-type and targeted alleles, respectively, as revealed by the external probe A. (B) Southern blot analysis of _Hin_dIII-digested tail DNA obtained from wild-type, BCMA+/− and BCMA−/− mice. (C) RT-PCR of splenic RNA samples obtained from wild-type and BCMA−/− mice. The 5′ RT-PCR identified the region corresponding to exon I of the gene. The housekeeping gene GADPH is included as control.
FIG. 2
B-cell populations in BCMA−/− mice, determined by flow cytometry analyses of B-cell populations found in bone marrow (A), spleens (B and C), and peritoneal cavities (D) of wild-type and BCMA−/− mice. Only IgM+ B cells are shown in panel C. Numbers indicate the percentages of cells within the lymphocyte forward and side scatter gates (A, B, and D) and percentages of IgM+ B cells for (D). The data shown are representative of more than five analyses.
FIG. 3
Distribution of various B-cell populations in spleens of BCMA−/− mice. The distribution of marginal zone (MZ), immature (Im), and follicular B cells as defined in Fig. 2C was examined in four wild-type (white boxes) and five mutant (black boxes) mice and expressed as percentage of total splenic B cells.
FIG. 4
Turnover of wild-type and BCMA-deficient B cells. Mice were continuously fed with BrdU in drinking water for a period of 1 or 3 weeks. B220+ IgM+ splenic and peritoneal cavity B cells were stained for intracellular BrdU content. Groups of four wild-type (white box) and five mutant (black box) mice were analyzed for each time point.
FIG. 5
Basal serum immunoglobulin levels in BCMA−/− mice. The concentrations of various serum immunoglobulin isotypes were measured by ELISA, and the value for each wild-type (open circles) and mutant (filled circles) mouse was plotted.
FIG. 6
BCMA−/− mice have normal T-cell-independent immune responses. Wild-type (open circles) and mutant (filled circles) mice were immunized with 10 μg of the T-cell-independent antigen NP-Ficoll. The amount of antigen-specific antibodies of the IgM and IgG3 class was measured in an ELISA 8 days after the challenge. The value for each mouse was plotted. Preimmune sera were negative for the antigen-specific antibodies and are not shown.
FIG. 7
Primary and secondary immune responses of BCMA-deficient mice to a high dose of T-cell-dependent antigen. Wild-type (open circles) and mutant (filled circles) mice were immunized with 200 μg of the alum-precipitated T-cell-dependent antigen NP-CG for the primary (10) response and reboosted at day 45 with 5 μg of the antigen for the secondary (20) immune response. Sera were collected from the mice at various time points after primary and secondary immunizations and quantified for the presence of NP-specific antibodies of the IgM and IgG1 classes. The immune sera were diluted as indicated. The value for each mouse was plotted. Preimmune sera were negative for the antigen-specific antibodies and are not shown.
FIG. 8
Primary and secondary immune responses of BCMA-deficient mice to a low dose of T-cell-dependent antigen. Wild-type (open circles) and mutant (filled circles) mice were immunized with 5 μg of alum-precipitated NP-CG and reboosted at day 45 with the same amount of the antigen. The ELISA was performed as for Fig. 7.
FIG. 9
Distribution of Syndecan-1-expressing B cells in BCMA−/− mice, determined by flow cytometry analyses of Syndecan-1-expressing B cells found in the spleens of naive mice (A) and wild-type and BCMA−/− mice 10 days post-NP-CG challenge (B). Numbers indicate percentages of total B cells present.
FIG. 10
Structures of primary follicles and germinal centers in spleens of BCMA-deficient mice. Cryosections of spleens from wild-type and mutant mice were stained with the indicated antibodies conjugated to FITC (green) or Texas red (red). Anti-IgM and anti-IgD stain B cells, anti-CD3 stains T cells, and peanut agglutinin (PNA) stains germinal center B cells.
FIG. 11
Semiquantitative RT-PCR of TACI expression in BCMA−/− mice. Total RNA was extracted from splenocytes of wild-type and BCMA−/− mice, and the reverse-transcribed cDNA was subjected to PCR for the numbers of cycles indicated. GADPH was amplified as a control for the amount of template present in the reaction.
Similar articles
- Selectivity of BAFF/BLyS and APRIL for binding to the TNF family receptors BAFFR/BR3 and BCMA.
Day ES, Cachero TG, Qian F, Sun Y, Wen D, Pelletier M, Hsu YM, Whitty A. Day ES, et al. Biochemistry. 2005 Feb 15;44(6):1919-31. doi: 10.1021/bi048227k. Biochemistry. 2005. PMID: 15697217 - APRIL and TALL-I and receptors BCMA and TACI: system for regulating humoral immunity.
Yu G, Boone T, Delaney J, Hawkins N, Kelley M, Ramakrishnan M, McCabe S, Qiu WR, Kornuc M, Xia XZ, Guo J, Stolina M, Boyle WJ, Sarosi I, Hsu H, Senaldi G, Theill LE. Yu G, et al. Nat Immunol. 2000 Sep;1(3):252-6. doi: 10.1038/79802. Nat Immunol. 2000. PMID: 10973284 - Identification of proteoglycans as the APRIL-specific binding partners.
Ingold K, Zumsteg A, Tardivel A, Huard B, Steiner QG, Cachero TG, Qiang F, Gorelik L, Kalled SL, Acha-Orbea H, Rennert PD, Tschopp J, Schneider P. Ingold K, et al. J Exp Med. 2005 May 2;201(9):1375-83. doi: 10.1084/jem.20042309. Epub 2005 Apr 25. J Exp Med. 2005. PMID: 15851487 Free PMC article. - The role of APRIL and BAFF in lymphocyte activation.
Schneider P. Schneider P. Curr Opin Immunol. 2005 Jun;17(3):282-9. doi: 10.1016/j.coi.2005.04.005. Curr Opin Immunol. 2005. PMID: 15886118 Review. - The uncertain glory of APRIL.
Medema JP, Planelles-Carazo L, Hardenberg G, Hahne M. Medema JP, et al. Cell Death Differ. 2003 Oct;10(10):1121-5. doi: 10.1038/sj.cdd.4401291. Cell Death Differ. 2003. PMID: 14502235 Review.
Cited by
- Therapeutic antibodies in oncology: an immunopharmacological overview.
Toledo-Stuardo K, Ribeiro CH, González-Herrera F, Matthies DJ, Le Roy MS, Dietz-Vargas C, Latorre Y, Campos I, Guerra Y, Tello S, Vásquez-Sáez V, Novoa P, Fehring N, González M, Rodríguez-Siza J, Vásquez G, Méndez P, Altamirano C, Molina MC. Toledo-Stuardo K, et al. Cancer Immunol Immunother. 2024 Oct 3;73(12):242. doi: 10.1007/s00262-024-03814-2. Cancer Immunol Immunother. 2024. PMID: 39358613 Free PMC article. Review. - Preclinical Evaluation of STI-8811, a Novel Antibody-Drug Conjugate Targeting BCMA for the Treatment of Multiple Myeloma.
Springer AD, Wang R, Wang J, Du Q, Pi W, Nguyen AQ, Li X, Khasanov A, Zhu T, Yan Z, Hong Y, Zhou H, Zhang Y, Kerwin L, Li L, Ji H, Zhang H. Springer AD, et al. Cancer Res Commun. 2024 Oct 1;4(10):2660-2672. doi: 10.1158/2767-9764.CRC-24-0413. Cancer Res Commun. 2024. PMID: 39292169 Free PMC article. - Halting multiple myeloma with MALT1 inhibition: suppressing BCMA-induced NF-κB and inducing immunogenic cell death.
Yao Y, Yuan M, Shi M, Li W, Sha Y, Zhang Y, Yuan C, Luo J, Li Z, Liao C, Xu K, Niu M. Yao Y, et al. Blood Adv. 2024 Aug 13;8(15):4003-4016. doi: 10.1182/bloodadvances.2023012394. Blood Adv. 2024. PMID: 38820414 Free PMC article. - Anti-BCMA novel therapies for multiple myeloma.
Sammartano V, Franceschini M, Fredducci S, Caroni F, Ciofini S, Pacelli P, Bocchia M, Gozzetti A. Sammartano V, et al. Cancer Drug Resist. 2023 Mar 22;6(1):169-181. doi: 10.20517/cdr.2022.138. eCollection 2023. Cancer Drug Resist. 2023. PMID: 37065871 Free PMC article. Review. - The BAFF-APRIL System in Cancer.
Ullah MA, Mackay F. Ullah MA, et al. Cancers (Basel). 2023 Mar 16;15(6):1791. doi: 10.3390/cancers15061791. Cancers (Basel). 2023. PMID: 36980677 Free PMC article. Review.
References
- Chambers C A, Allison J P. Co-stimulation in T cell responses. Curr Opin Immunol. 1997;9:396–404. - PubMed
- Forster I, Muller W, Schittek B, Rajewsky K. Generation of long-lived B cells in germ-free mice. Eur J Immunol. 1991;21:1779–1782. - PubMed
- Fu Y X, Chaplin D D. Development and maturation of secondary lymphoid tissues. Annu Rev Immunol. 1999;17:399–433. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials
Miscellaneous